Young P J, Lederer C, Eder K, Daumer M, Neiss A, Polman C, Kappos L
Sylvia Lawry Centre for Multiple Sclerosis Research, Munich, Germany.
Neurology. 2006 Sep 12;67(5):804-8. doi: 10.1212/01.wnl.0000234064.17156.03.
To investigate whether relapses contribute to the development of subsequent sustained increase of impairment and disability in patients with multiple sclerosis (MS).
In a random sampled subset of 256 relapsing-remitting MS (RRMS) patients from the placebo arms of 20 randomized, controlled clinical trials contained in the Sylvia Lawry Centre for MS Research (SLCMSR) open database (mean follow-up time 2.66 years), the authors tested whether time to an increase of the Expanded Disability Status Scale (EDSS) score (confirmed after 6 months) was related to the occurrence of prior relapses. In the primary analysis, EDSS progressions starting within the period used to calculate the on-study relapse rate (sacrifice period) were not counted. The result obtained was then validated in an independent validation part of the SLCMSR database (n = 320).
Although in the first subset of 256 RRMS patients, occurrence of relapses in the first 4 months on study appeared to be the best predictor for a shorter time to subsequent sustained increase in the EDSS score (hazard ratio [HR] 2.26 [95% CI: 1.36 to 3.75]), this finding was not confirmed in the validation dataset (HR 1.35, one-sided Wald test, lower limit of the 95% CI: 0.90).
Although relapses may result into permanent damage and Expanded Disability Status Scale (EDSS) progression, there is no consistent effect of on-study relapses on the subsequent development of sustained EDSS score increase during a typical clinical study observation period.
探讨复发是否会促使多发性硬化症(MS)患者随后出现功能障碍和残疾的持续加重。
在西尔维亚·劳里多发性硬化症研究中心(SLCMSR)开放数据库中20项随机对照临床试验安慰剂组的256例复发缓解型MS(RRMS)患者的随机抽样子集中(平均随访时间2.66年),作者测试了扩展残疾状态量表(EDSS)评分增加的时间(6个月后确认)是否与既往复发的发生有关。在主要分析中,未计算在用于计算研究期间复发率的时间段(牺牲期)内开始的EDSS进展。然后在SLCMSR数据库的独立验证部分(n = 320)中对所得结果进行验证。
尽管在256例RRMS患者的第一个子集中,研究开始后前4个月内的复发似乎是随后EDSS评分持续增加时间缩短的最佳预测指标(风险比[HR] 2.26 [95% CI:1.36至3.75]),但这一发现未在验证数据集中得到证实(HR 1.35,单侧Wald检验,95% CI下限:0.90)。
尽管复发可能导致永久性损伤和扩展残疾状态量表(EDSS)进展,但在典型的临床研究观察期内,研究期间的复发对随后持续的EDSS评分增加的发展没有一致的影响。